Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing
 

This report describes and analyzes the field of Targeted Protein Degradation (TPD) from an industry perspective as of March 2022.

The report provides essential information about and analysis of

  • Pure-play TPD technology companies (molecular glues, heterobifunctional degraders, lysosomal and autophagic pathway degraders);
  • Diversified technology companies with a TPD platform;
  • Major pharma companies with a stake in TPD (in-house, partnering, licensing, acquisition);
  • Proteasomal protein degrader technologies (heterobifunctional, molecular glue, monovalent degrader);
  • Rational approaches for monofunctional molecular glue discovery at industry scale;
  • Lysosomal and autophagy pathway degrader technologies (LYTACs, AUTOTACs, ATTECs etc);
  • Clinical and preclinical experience with molecular glues and PROTACs;
  • Profiles of TPD Drug Candidates;
  • TPD Pipeline Analysis;
  • Preferred Targets of TPDs;
  • Preferred E3 ligases and their binders;
  • Technologies for discovery of binders to proteins-of-interest and E3 ligases;
  • Venture capital financing of TPD technology companies;
  • Financing by IPO and follow-on public offerings;
  • Revenues from TPD discovery and licensing deals.
Targeted protein degradation is a strongly and rapidly emerging new therapeutic modality based on the promise to overcome limitations of traditional small molecule drug modalities, such as limited access to difficult-to-drug targets and development of drug resistance. TPD technology is being adopted by most major pharmaceutical companies as it is regarded as a key technology platform. Pure-play TPD technology companies make progress by advancing their drug candidates into clinical studies. Many biotech companies are diversifying their platforms by adding TPD technology.

Investors welcome companies with TPD technologies as evidenced by the continuous flow of money to foster development of TPD technology and TPD drug candidates. Since April of 2020, five pure-play TPD technology companies went public and successfully raised a total of US$ 2.14 bln. The average market capitalization of five NASDAQ listed TPD technology companies was US$ 1.5 bln as of March 4, 2022. Series A-E financing rounds of 23 pure-play TPD technology companies brought in a total of US$ 1,778 mln of venture capital and equity investment. Partnering revenues are another important source of funding. As the TPD pipeline is maturing with favorable clinical outcomes, a recent licensing deal for a clinical phase II estrogen receptor PROTAC justified up-front payment and equity investment of US$ 1 bln.

This report describes and analyzes the industry landscape of targeted protein degradation by proteasomal-, lysosomal- and autophagy-targeted technologies. The report is based on information retrieved from 69 technology companies, 23 pharmaceutical companies and three academic institutions with publicly known industry ties.

The report includes Tables which summarize specific information to allow comprehensive comparisons. Illustrations are used to explain the mechanism of action of the various TPD technologies, pharmacologic effects and molecular structures.

Whenever possible, the profiles of TPD technology companies address the following aspects:

  • General overview (founders, foundation year, technology source, location, number of employees), non-TPD technologies if applicable;
  • Financial situation and funding history;
  • Technology overview;
  • Partnering;
  • Pipeline.
Description of pharmaceutical companies generally is limited to activities with respect to TPD for publicly known in-house activities, for R&D collaboration and licensing and for acquisitions (Merck, Bayer, Amgen and Bristol Myers Squib).

The heterogenous profiles of the 69 technology companies demands assignation to “clusters” of companies with similar characteristics to allow a systematic comparison of 33 pure-play TPD technology companies focused on proteasomal pathway or non-proteasomal pathway technologies; 26 technologically diversified companies with TPD technologies; and the remainder of 10 companies.

Specific profiles are provided for 31 TPD technologies, separately for proteasomal molecular glue/monovalent degrader; proteasomal heterobifunctional degraders, lysosomal & autophagy pathway degraders and the remainder.

Specific profiles are provided for 48 TPD drug candidates, separately for the same four TPD modalities as for TPD technologies.

All information in the three chapters of Company Profiles, Technology Profiles and Drug Candidate Profiles are fully referenced with 117 scientific references, in most cases with hyperlinks with immediate online access to the source of information (abstracts, Poster, Presentations). Non-scientific references, such as press releases, annual reports or company presentations, are disclosed within the text with an embedded hyperlink leading to the source of information. Details about R&D strategy, collaboration and licensing agreements, acquisitions, financing rounds and sources are described in the company profiles.

What will you find in the report?

  • Profiles of pure-play and diversified Targeted Protein Degrader (TPD technology companies;
  • Description of Big Pharma’s role in the field (in-house R&D, partnering, acqusition and investing);
  • Comprehensive description and analysis of emerging proteasomal and lysosomal/autophagic TPD technologies;
  • TPD Technology selection and preferences of major pharma;
  • Analysis of TPD technologies;
  • Technologies for discovery of molecular glues, difficult to drug targets and E3 ligase binders;
  • Pharmacologic profiles of Targeted Protein Degraders (TPD);
  • Target selection, pipeline analysis and competition of drug candidates;
  • Description and analysis of financing rounds (capital raised, investors);
  • Economic terms of collaboration and licensing deals;
  • Sources of financing.

    •  
Who will benefit from the report?
  • Venture capital, private equity and investment managers;
  • Managers of Big Pharma venture capital firms;
  • Financial analysts;
  • Business development and licensing (BDL) specialists;
  • CEO, COO and managing directors;
  • Corporate strategy analysts and managers;
  • Chief Technology Officer;
  • R&D Portfolio, Technology and Strategy Management;
  • Clinical and preclinical development specialists.